4-[6-氧代-3-(2-苯基吡唑并[1,5-a]吡啶-3-基)哒嗪-1-基]丁酸 | 131185-37-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-[6-氧代-3-(2-苯基吡唑并[1,5-a]吡啶-3-基)哒嗪-1-基]丁酸
• 英文名称: 3-[2-(3-carboxypropyl)-3-oxo-2,3-dihydropyridazin-6-yl]-2-phenylpyrazolo[1,5-a]pyridine
• 英文别名: FK 838；3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazine-6-one butyric acid；4-[6-Oxo-3-(2-phenyl-pyrazolo[1,5-a]pyridin-3-yl)-6H-pyridazin-1-yl]-butyric acid；6-Oxo-3-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-1(6H)-pyridazinebutyric acid；4-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)pyridazin-1-yl]butanoic acid
• CAS: 131185-37-0
• 化学式: C₂₁H₁₈N₄O₃
• 分子量: 374.399
• InChiKey: FKJPZJACCBMNKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  87.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)ethanone 在 苄基三乙基氯化铵 、 potassium carbonate 、 一水合肼 、 溶剂黄146 、 sodium hydroxide 作用下， 以 甲醇 、 乙二醇二甲醚 、 水 、 乙酸乙酯 为溶剂， 反应 14.0h， 生成 4-[6-氧代-3-(2-苯基吡唑并[1,5-a]吡啶-3-基)哒嗪-1-基]丁酸
  参考文献：
  名称：

  Pilot-Scale Synthesis of a Novel Non-Xanthine Adenosine A₁ Receptor Antagonist. 1,3-Dipolar Cycloaddition of Pyridine N-Imine to an Acetylene

  摘要：

  Adenosine A(1) receptor antagonist, FK838, has been synthesized in 44% overall yield by a five-step sequence which is operationally straightforward and readily carried out on a large scale, Investigations into the 1,3 dipolar cycloaddition process that afforded a pyrazolo[1,5-a]pyridine derivative are also described. Process improvements and optimization of each step permitted elimination of column chromatography, resulting in a practical and cost effective synthesis of FK838, These methods were successfully scaled up in a pharmaceutical pilot plant to give bulk drug used in clinical trials.

  DOI：

  10.1021/op980039c

文献信息

• Methods of treating pulmonary disease
  申请人：——

  公开号：US20040259889A1

  公开（公告）日：2004-12-23

  Methods useful for reducing pulmonary vasoconstriction or improving pulmonary hemodynamics in a patient are disclosed. More particularly, this invention relates to administering A 1 adenosine receptor antagonists to reduce pulmonary vasoconstriction and improve pulmonary hemodynamics.

  本发明涉及使用A1腺苷受体拮抗剂来减少肺血管收缩并改善肺血液动力学。
• [EN] PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA<br/>[FR] COMPOSES DE PYRAZOLOPYRIDINE DESTINES AU TRAITEMENT DE L'ANEMIE
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1993025205A1

  公开（公告）日：1993-12-23

  (EN) The present invention relates to a pharmaceutical composition for the prevention and/or the treatment of anemia in a human being or an animal which comprises, as an active ingredient, a pyrazolopyridine compound of formula (I) wherein R1 is lower alkyl, etc, R2 is a group of formula (II) (wherein R4 is protected amino, etc, and R5 is hydrogen, etc); etc, and R3 is hydrogen, etc, or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier or excipient, etc.(FR) Composition pharmaceutique destinée à la prévention et/ou au traitement de l'anémie chez l'être humain ou chez l'animal. Cette composition comprend comme ingrédient actif un composé de pyrazolopyridine de la formule (I), dans laquelle R1 est un alkyle inférieur, etc.; R2 est un groupe de la formule (II), dans laquelle R4 est un amino protégé, etc. et R5 est l'hydrogène, etc.; etc. et R3 est l'hydrogène, etc.; ou un sel pharmaceutiquement acceptable de ce composé, mélangé à un excipient pharmaceutiquement acceptable, etc.

  本发明涉及一种药物组合物，用于预防和/或治疗人类或动物的贫血，其作为活性成分包含式（I）的吡唑啉并吡啶化合物，其中R1是低碳基等，R2是式（II）的基团（其中R4是保护氨基等，R5是氢等）等，R3是氢等，或其药学上可接受的盐与药学上可接受的载体或赋形剂等混合物。
• Method of treatment using pyrazolopyridine compound
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US05155114A1

  公开（公告）日：1992-10-13

  The invention relates to a method for the prevention and/or treatment of renal toxicity, nephrosis or nephritis, which comprises administering a pyrazolopyridine compound of the formula: ##STR1## wherein R.sup.1 is aryl, and R.sup.2 is unsaturated heterocyclic group which contains at least one heteroatom selected from the group consisting of N, O and S, which may have one or more suitable substituent(s), or a pharmaceutically acceptable salt thereof to a human being or an animal.

  本发明涉及一种预防和/或治疗肾毒性、肾病综合症或肾炎的方法，其中包括向人类或动物给予式如下的吡唑啉并吡啶化合物：##STR1## 其中R.sup.1是芳基，R.sup.2是不饱和杂环基团，其中包含至少一种从N、O和S组成的杂原子，可以具有一个或多个适当的取代基，或其药学上可接受的盐。
• Pyrazolopyridine compound and processes for preparation thereof
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04985444A1

  公开（公告）日：1991-01-15

  The invention relates to pyrazolopyridine compounds for the treatment of melancholia, heart failure, hypertension, renal insufficiency, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, myocardiac infection, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack or angina pectoris, said compounds being of the formula ##STR1## wherein R.sup.1 is aryl, and R.sup.2 is unsaturated heterocyclic group which contains at least one heteroatom selected from the group consisting of N, O and S, which may have one or more suitable substituent(s), or a pharmaceutically acceptable salt thereof.

  本发明涉及用于治疗忧郁症、心力衰竭、高血压、肾功能不全、水肿、肥胖症、支气管哮喘、痛风、高尿酸血症、婴儿猝死综合征、免疫抑制、糖尿病、心肌感染、血栓形成、梗阻、闭塞性动脉硬化、静脉炎、脑梗死、短暂性脑缺血发作或心绞痛的吡唑吡啶化合物，所述化合物的结构式为##STR1##其中R.sup.1是芳基，R.sup.2是不饱和杂环基，其含有至少一种来自N、O和S的杂原子，可能具有一种或多种适当的取代基，或其药学上可接受的盐。
• Pyrazine Derivatives Useful as Adenosine Receptor Antagonists
  申请人：Vidal Juan Bernat

  公开号：US20090042891A1

  公开（公告）日：2009-02-12

  The present disclosure relates to a compound of formula (I) wherein: A is an optionally substituted monocyclic or polycyclic aryl or heteroaryl group; B is an optionally substituted monocyclic nitrogen-containing heteroaryl group; and either a) R 1 and R 2 are chosen from a hydrogen atom and specified substituents, or b) R 2 , R 1 and the —NH— group to which R 1 is attached, form a moiety chosen from the moiety of formulae (IIa) and (IIb): or a pharmaceutically acceptable salt thereof, or a N-oxide thereof. The present disclosure also relates to a method for treating a subject afflicted with a pathological condition or disease susceptible to amelioration by antagonism of the A 2B adenosine receptor.

  本公开涉及一种式（I）的化合物，其中：A是可选取的取代的单环或多环芳基或杂芳基基团；B是可选取的取代的单环含氮杂芳基基团；并且要么a）R1和R2选择自氢原子和指定的取代基，要么b）R2、R1和R1附着的—NH—基团形成式（IIa）和（IIb）的基团：或其药学上可接受的盐或其N-氧化物。本公开还涉及一种治疗患有病理状况或疾病，易于通过拮抗A2B腺苷受体而改善的受试者的方法。

表征谱图